Human head and neck squamous cell carcinoma - Associated semaphorin 4D induces expansion of myeloid-derived suppressor cells

Journal of Immunology

Volumn 196, Issue 3, 2016, Pages 1419-1429

  Younis, Rania H ^a,b   Han, Kyu Lee ^a   Webb, Tonya J ^a,c  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; SEMAPHORIN; SEMAPHORIN 4D; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CD100 ANTIGEN; LEUKOCYTE ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SUPPRESSOR CELL; BONE MARROW CELL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEAD AND NECK TUMOR; IMMUNOBLOTTING; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TUMOR ESCAPE;

ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; MYELOID CELLS; RNA, SMALL INTERFERING; SEMAPHORINS; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; TUMOR ESCAPE;

EID: 84957626612     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501293     Document Type: Article

References (67)

1. Siegel, R. L., K. D. Miller, and A. Jemal. 2015. Cancer statistics, 2015. CA Cancer J. Clin. 65: 5-29.
2. Hadden, J. W., J. Endicott, P. Baekey, P. Skipper, and E. M. Hadden. 1994. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 120: 395-403.
3. Katz, A. E. 1993. Update on immunology of head and neck cancer. Med. Clin. North Am. 77: 625-631.
4. Vlock, D. R. 1991. Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates. Hematol. Oncol. Clin. North Am. 5: 797-820.
5. Russell, S. M., M. G. Lechner, L. Gong, C. Megiel, D. J. Liebertz, R. Masood, A. J. Correa, J. Han, R. K. Puri, U. K. Sinha, and A. L. Epstein. 2011. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 47: 810-817.
6. Gildener-Leapman, N., R. L. Ferris, and J. E. Bauman. 2013. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 49: 1089-1096.
7. + myeloid-derived suppressor cell subsets induced from peripheral blood mono-nuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9: 90.
8. Vasquez-Dunddel, D., F. Pan, Q. Zeng, M. Gorbounov, E. Albesiano, J. Fu, R. L. Blosser, A. J. Tam, T. Bruno, H. Zhang, et al. 2013. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123: 1580-1589.
9. Gabitass, R. F., N. E. Annels, D. D. Stocken, H. A. Pandha, and G. W. Middleton. 2011. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60: 1419-1430.
10. Filipazzi, P., V. Huber, and L. Rivoltini. 2012. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61: 255-263.
11. low/2 monocytes in prostate cancer. Prostate 70: 443-455.
12. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
13. Talmadge, J. E., and D. I. Gabrilovich. 2013. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13: 739-752.
14. Lechner, M. G., D. J. Liebertz, and A. L. Epstein. 2010. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185: 2273-2284.
15. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
16. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
17. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenviron-ment. J. Exp. Med. 207: 2439-2453.
18. Capparuccia, L., and L. Tamagnone. 2009. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment-two sides of a coin. J. Cell Sci. 122: 1723-1736.
19. + cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1: 95-103.
20. + natural suppressor cells. Int. J. Cancer 74: 69-74.
21. Kolodkin, A. L., D. J. Matthes, and C. S. Goodman. 1993. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75: 1389-1399.
22. Delaire, S., A. Elhabazi, A. Bensussan, and L. Boumsell. 1998. CD100 is a leukocyte semaphorin. Cell. Mol. Life Sci. 54: 1265-1276.
23. Roth, L., E. Koncina, S. Satkauskas, G. Crémel, D. Aunis, and D. Bagnard. 2009. The many faces of semaphorins: from development to pathology. Cell. Mol. Life Sci. 66: 649-666.
24. Bismuth, G., and L. Boumsell. 2002. Controlling the immune system through semaphorins. Sci. STKE 2002: re4.
25. Shi, W., A. Kumanogoh, C. Watanabe, J. Uchida, X. Wang, T. Yasui, K. Yukawa, M. Ikawa, M. Okabe, J. R. Parnes, et al. 2000. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell acti-vation in CD100-deficient mice. Immunity 13: 633-642.
26. Tamagnone, L., and P. M. Comoglio. 2004. To move or not to move? Sem - Aphorin signalling in cell migration. EMBO Rep. 5: 356-361.
27. Ishida, I., A. Kumanogoh, K. Suzuki, S. Akahani, K. Noda, and H. Kikutani. 2003. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int. Immunol. 15: 1027-1034.
28. Elhabazi, A., V. Lang, C. Hérold, G. J. Freeman, A. Bensussan, L. Boumsell, and G. Bismuth. 1997. The human semaphorin-like leukocyte cell surface molecule CD100 associates with a serine kinase activity. J. Biol. Chem. 272: 23515-23520.
29. Okuno, T., Y. Nakatsuji, M. Moriya, H. Takamatsu, S. Nojima, N. Takegahara, T. Toyofuku, Y. Nakagawa, S. Kang, R. H. Friedel, et al. 2010. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 184: 1499-1506.
30. Chabbert-de Ponnat, I., A. Marie-Cardine, R. J. Pasterkamp, V. Schiavon, L. Tamagnone, N. Thomasset, A. Bensussan, and L. Boumsell. 2005. Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. Int. Immunol. 17: 439-447.
31. Delaire, S., C. Billard, R. Tordjman, A. Chédotal, A. Elhabazi, A. Bensussan, and L. Boumsell. 2001. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J. Immunol. 166: 4348-4354.
32. Basile, J. R., R. M. Castilho, V. P. Williams, and J. S. Gutkind. 2006. Semaphorin 4D provides a link between axon guidance processes and tumor-induced an-giogenesis. Proc. Natl. Acad. Sci. USA 103: 9017-9022.
33. Zhou, H., Y. H. Yang, N. O. Binmadi, P. Proia, and J. R. Basile. 2012. The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular en-dothelial growth factor promote tumor growth and angiogenesis in oral squa-mous cell carcinoma. Exp. Cell Res. 318: 1685-1698.
34. Zhou, H., N. O. Binmadi, Y. H. Yang, P. Proia, and J. R. Basile. 2012. Sem - Aphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 15: 391-407.
35. Mu, L., J. Wang, X. Guo, S. Zheng, K. Shan, C. Jing, and L. Li. 2014. [Correlation and clinical significance of expressions of HIF-1a and Sema4D in co-lorectal carcinoma tissues]. Zhonghua Wei Chang Wai Ke Za Zhi 17: 388-392.
36. Liu, H., Y. Yang, J. Xiao, S. Yang, Y. Liu, W. Kang, X. Li, and F. Zhang. 2014. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients. Microvasc. Res. 93: 1-8.
37. Ch'ng, E. S., and A. Kumanogoh. 2010. Roles of Sema4D and Plexin-B1 in tumor progression. Mol. Cancer 9: 251.
38. Chen, Y., L. Zhang, Y. Pan, X. Ren, and Q. Hao. 2012. Over-expression of semaphorin4D, hypoxia-inducible factor-1a and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int. J. Mol. Sci. 13: 13264-13274.
39. Sierra, J. R., S. Corso, L. Caione, V. Cepero, P. Conrotto, A. Cignetti, W. Piacibello, A. Kumanogoh, H. Kikutani, P. M. Comoglio, et al. 2008. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor - Associated macrophages. J. Exp. Med. 205: 1673-1685.
40. Martin, D., M. C. Abba, A. A. Molinolo, L. Vitale-Cross, Z. Wang, M. Zaida, N. C. Delic, Y. Samuels, J. G. Lyons, and J. S. Gutkind. 2014. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget 5: 8906-8923.
41. Chouaib, S., Y. Messai, S. Couve, B. Escudier, M. Hasmim, and M. Z. Noman. 2012. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 3: 21.
42. Kumanogoh, A., and H. Kikutani. 2003. Immune semaphorins: a new area of semaphorin research. J. Cell Sci. 116: 3463-3470.
43. Cuenca, A. G., M. J. Delano, K. M. Kelly-Scumpia, C. Moreno, P. O. Scumpia, D. M. Laface, P. G. Heyworth, P. A. Efron, and L. L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17: 281-292.
44. Tong, C. C., J. Kao, and A. G. Sikora. 2012. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol. Res. 54: 266-274.
45. Young, M. R., and D. M. Lathers. 1999. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int. J. Immuno-pharmacol. 21: 241-252.
46. 2 cells in squamous cell carcinoma of the head and neck. Cancer Sci. 103: 976-983.
47. + cells within human head and neck squamous cell carcinomas. J. Immunol. 159: 990-996.
48. Evans, E. E., A. S. Jonason, Jr., H. Bussler, S. Torno, J. Veeraraghavan, C. Reilly, M. A. Doherty, J. Seils, L. A. Winter, C. Mallow, et al. 2015. Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol. Res. 3: 689-701.
49. Tartour, E., H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, et al. 2011. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of anti - Angiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30: 83-95.
50. Kovacsovics-Bankowski, M., L. Chisholm, J. Vercellini, C. G. Tucker, R. Montler, D. Haley, P. Newell, J. Ma, P. Tseng, R. Wolf, et al. 2014. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J. Immunother. Cancer 2: 38.
51. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117: 1466-1476.
52. Kumanogoh, A., K. Suzuki, E. Ch'ng, C. Watanabe, S. Marukawa, N. Takegahara, I. Ishida, T. Sato, S. Habu, K. Yoshida, et al. 2002. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J. Immunol. 169: 1175-1181.
53. Kataoka, T. R., A. Kumanogoh, M. Hirata, K. Moriyoshi, C. Ueshima, M. Kawahara, T. Tsuruyama, and H. Haga. 2013. CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1. Sci. Rep. 3: 2861.
54. Kumanogoh, A., S. Marukawa, K. Suzuki, N. Takegahara, C. Watanabe, E. Ch'ng, I. Ishida, H. Fujimura, S. Sakoda, K. Yoshida, and H. Kikutani. 2002. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419: 629-633.
55. Yang, Y. H., H. Zhou, N. O. Binmadi, P. Proia, and J. R. Basile. 2011. Plexin-B1 activates NF-kB and IL-8 to promote a pro - Angiogenic response in endothelial cells. PLoS One 6: e25826.
56. + cell activation leading to pathogenetic humoral responses and immune complex glomerulonephritis. J. Immunol. 177: 3406-3412.
57. Kusmartsev, S., and D. I. Gabrilovich. 2006. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of my-eloid cells in cancer. Cancer Metastasis Rev. 25: 323-331.
58. Xiang, X., A. Poliakov, C. Liu, Y. Liu, Z. B. Deng, J. Wang, Z. Cheng, S. V. Shah, G. J. Wang, L. Zhang, et al. 2009. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 124: 2621-2633.
59. Thomas, G. R., Z. Chen, E. Leukinova, C. Van Waes, and J. Wen. 2004. Cyto-kines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol. Immunother. 53: 33-40.
60. Piva, M. R., L. B. DE Souza, P. R. Martins-Filho, R. C. Soares, T. DE Santana Santos, and E. S. DE Souza Andrade. 2011. Role of inflammation in oral car-cinogenesis (part I): Histological grading of malignancy using a binary system. Oncol. Lett. 2: 1225-1231.
61. Piva, M. R., L. B. DE Souza, P. R. Martins-Filho, C. F. Nonaka, T. DE Santana Santos, E. S. DE Souza Andrade, and D. Piva. 2013. Role of inflammation in oral carcinogenesis (Part II): CD8, FOXP3, TNF - A, TGF-b and NF-kB expression. Oncol. Lett. 5: 1909-1914.
62. + B lymphocytes. Blood 101: 1962-1969.
63. Finke, J., J. Ko, B. Rini, P. Rayman, J. Ireland, and P. Cohen. 2011. MDSC as a mechanism of tumor escape from sunitinib mediated anti - Angiogenic therapy. Int. Immunopharmacol. 11: 856-861.
64. Szala, S., I. Mitrus, and A. Sochanik. 2010. Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy? Cancer Immunol. Immunother. 59: 1449-1455.
65. Strauss, L., D. Volland, A. Guerrero, and T. Reichert. 2005. [Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squa-mous cell carcinoma (HNSCC)]. Mund Kiefer Gesichtschir. 9: 273-281.
66. Strauss, L., D. Volland, M. Kunkel, and T. E. Reichert. 2005. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med. Sci. Monit. 11: BR280-BR292.
67. Dolcetti, L., I. Marigo, B. Mantelli, E. Peranzoni, P. Zanovello, and V. Bronte. 2008. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 267: 216-225.